Loading...
XKRX
005257
Market cap545mUSD
Jul 11, Last price  
36,100.00KRW
1D
-2.43%
1Q
93.05%
Jan 2017
69.48%
Name

Green Cross Holdings

Chart & Performance

D1W1MN
XKRX:005257 chart
No data to show
P/E
—
P/S
0.97
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-22.66%
Rev. gr., 5y
1.96%
Revenues
1.68t
-18.37%
629,534,600,000533,618,697,000680,231,174,000832,291,097,000817,434,910,350855,344,622,740934,622,237,8301,043,840,314,4201,132,119,623,9101,353,893,060,7901,464,875,446,0901,547,971,214,0401,524,799,074,0001,719,325,650,4101,840,558,603,0002,079,559,971,0002,057,935,704,6101,679,891,941,470
Net income
-26.28b
L-51.46%
24,577,921,00021,360,397,00037,606,976,00067,522,188,00027,675,146,00061,546,845,80043,549,742,61056,760,788,98065,420,806,36047,176,642,04043,364,195,34018,466,539,830-30,476,551,59070,361,211,020127,657,537,37058,897,358,700-54,136,304,800-26,280,215,150
CFO
-53.46b
L+34.81%
262,766,269,000167,466,117,000482,604,136,000355,618,664,000116,177,695,40036,796,180,23017,568,307,99054,542,863,2307,035,743,480-805,469,520144,482,443,82037,643,839,2907,650,391,89038,138,268,880103,769,151,07097,156,791,410-39,654,746,609-53,460,079,250
Dividend
Dec 27, 2023305 KRW/sh
Earnings
Aug 12, 2025

Profile

Green Cross Holdings Corporation operates as a biotechnology company. The company provides plasma derivatives, prescription drugs, over the counter drugs, and hunter syndrome drugs; and vaccines for hemorrhagic fever, varicella, hepatitis-B, and flu. It also researches and develops oncology, immunology, and cell therapy products; and offers recombinant protein treatment for hemophilia. The company has partnerships and collaborations with biotech companies and academia for development of new drugs and technologies. Green Cross Holdings was founded in 1967 and is headquartered in Yongin, South Korea.
URL
http://www.greencross.com
IPO date
Aug 28, 1978
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,679,891,941
-18.37%
2,057,935,705
-1.04%
2,079,559,971
12.99%
Cost of revenue
1,494,273,594
1,874,593,622
1,792,909,375
Unusual Expense (Income)
NOPBT
185,618,347
183,342,083
286,650,596
NOPBT Margin
11.05%
8.91%
13.78%
Operating Taxes
1,527,336
(9,469,931)
(29,267,887)
Tax Rate
0.82%
NOPAT
184,091,012
192,812,014
315,918,483
Net income
(26,280,215)
-51.46%
(54,136,305)
-191.92%
58,897,359
-53.86%
Dividends
(19,532,262)
(29,933,111)
(31,499,998)
Dividend yield
8.98%
4.03%
4.08%
Proceeds from repurchase of equity
24,865,561
BB yield
-3.35%
Debt
Debt current
392,224,795
868,835,227
489,119,856
Long-term debt
546,632,909
303,165,937
529,710,069
Deferred revenue
14,570,000
15,884,214
22,693,024
Other long-term liabilities
38,834,822
46,922,339
32,133,139
Net debt
690,953,878
484,612,881
438,453,153
Cash flow
Cash from operating activities
(53,460,079)
(39,654,747)
97,156,791
CAPEX
(31,991,845)
(89,962,142)
(127,180,576)
Cash from investing activities
(67,894,170)
(134,347,170)
(283,962,799)
Cash from financing activities
93,845,335
140,559,850
51,336,156
FCF
99,187,809
155,314,505
392,131,880
Balance
Cash
23,995,031
196,111,169
239,977,438
Long term investments
223,908,796
491,277,113
340,399,333
Excess cash
163,909,229
584,491,497
476,398,773
Stockholders' equity
1,102,139,112
1,843,691,203
2,439,510,211
Invested Capital
1,970,282,793
2,480,345,066
2,498,679,645
ROIC
8.27%
7.74%
12.98%
ROCE
7.84%
5.93%
9.52%
EV
Common stock shares outstanding
12,564
45,402
45,402
Price
17,320.00
5.93%
16,350.00
-3.82%
17,000.00
-37.38%
Market cap
217,606,887
-70.69%
742,318,302
-3.82%
771,829,427
-37.38%
EV
1,136,931,546
2,128,220,924
2,140,849,306
EBITDA
266,652,514
278,189,001
365,306,431
EV/EBITDA
4.26
7.65
5.86
Interest
40,439,237
53,104,000
36,475,000
Interest/NOPBT
21.79%
28.96%
12.72%